Blue Jet Healthcare is listed at a premium of 9.8%. Is it better to book, hold, or acquire a profit?

 Blue Jet Healthcare is listed at a premium of 9.8%. Is it better to book, hold, or acquire a profit?

Long-term ownership of Blue Jet Healthcare shares is advised by analysts.

Blue Jet Healthcare was able to raise Rs 840.27 crore via the IPO.

Blue Jet Healthcare's shares had a great market debut, going public on November 1 at a 9.8% premium to the IPO price of Rs 346. On the NSE, the shares started at Rs 380, while on the BSE, they opened at Rs 359 per.

Due to the company's excellent financial performance, experts now advise keeping the shares for the long run. The public offering got a respectable reaction from investors.

The shares increased by up to 16 percent above the issue price shortly after listing, reaching an intraday high of Rs 402.35 on the NSE. With its public offering, which took place between October 25 and October 27 for subscriptions, Blue Jet Healthcare was able to generate Rs 840.27 crore. It was all a 2.42 crore share offer for sale. A price range of Rs 329–346 per share was established.

Is it better to hold, sell, or buy Blue Jet Healthcare stock? Let's see what the experts have to say.

Hold Swastika Investmart

Blue Jet Healthcare has a significant competitive edge because of its high entry barriers and enduring connections with global clients. According to Shivani Nyati, head of wealth at Swastika Investmart Ltd., the company's financial performance is likewise solid, with steady rise in both sales and profit in recent years. She suggested that investors maintain a stop loss around Rs 340 in order to retain the shares.

Hold on, Stoxbox

In FY23, the company's ROE and ROCE were 26.6 percent and 31.9 percent, respectively. "The company's performance is expected to be driven going forward by the growth of the contract development and manufacturing organization (CDMO) model, strong financial performance, and expanding production capacity," said Prathamesh Masdekar, Research Analyst at StoxBox. Masdekar is still upbeat about the situation and advises allotteed investors to hang onto their shares and think about purchasing them at lower prices in the medium to long run.

Mehta Stocks: Record Gain

Blue Jet Healthcare's IPO performed better than street estimates in spite of the gloomy state of the market. Mehta Equities Ltd.'s senior vice-president of research and research analyst Prashanth Tapse feels that the listing premium makes sense given its array of specialized products. Tapse gave cautious investors advice to book profits, telling those who wanted to purchase more to hold off and wait for the market to level out in light of reasonable long-term industry reasons.